Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-02-10
1995-05-30
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, A61K 3736, C07G 700
Patent
active
054201110
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates generally to a method and/or medicament for reducing fetal growth retardation and relates particularly though not necessarily solely to the use of maternally administered IGF-1, IGF-2 or analogues thereof or a combination of these compounds to promote fetal growth by reducing maternal constraint.
BACKGROUND ART
Fetal growth retardation is a major cause of perinatal morbidity and mortality both in farm animals and in man.
In man, intrauterine growth retardation is a major cause of perinatal death either due to late abortion, stillbirth or neonatal death particularly in prematurely delivered infants. No effective intrauterine therapy is known even though its diagnosis in utero by ultrasound for example is routine. The main therapy is bedrest. Growth retarded infants who survive have a far greater risk of asphyxial brain damage leading to sensory defects, cerebral palsy, learning disorders, epilepsy, or intellectual retardation. They also may exhibit severe and continuing growth failure.
In farm animals, intrauterine growth retardation leads to a greater risk of perinatal loss particularly from stillbirth or from hypothermia (due to insufficient metabolic fuel available after birth). Growth retardation often persists and is seen as the "runt" which causes a large economic loss to farmers. Such runts are common in sheep, cattle, goats, deer, and particularly in pigs. No effective therapy or prophylactic approach other than selective breeding is known. The "runt problem" has limited the ability for new breeds of high fecundity (e.g. the Boroola merino sheep) to be economically introduced.
In one publication (Blair et al., Endo 123: 1690-1692, 1988) experiments where described wherein three lines of mice where derived by genetic selection based on their levels of IGF-1 secretion. These were termed "control" mice and "high line" and "low line" IGF-1 mice. It was found that mice secreting higher amounts of IGF-1 had larger placentae and fetuses than the conrol and low-line mice.
However, the above study did not define whether the observation that larger fetuses were born to high-line IGF-1 mice was a coincidence based on the experimental design, or whether it was due to a difference in fetal, placetal or maternal IGF-1 secretion.
Contemporary publications indicate that IGF-1 does not cross the placenta (Davenport et al., i Endo. 127: 1278-1287, 1990). Thus, it appeared unlikely that the increase in fetal size was due to an increase in maternal IGF-1 secretion. In light of this, there has been no interest in the potential for maternally administered IGF-1 to affect fetal development.
Accordingly, it is an object of the invention to provide a method and/or medicament for reducing fetal growth retardation which will at least provide the public with a useful choice.
It is a further object of the invention to provide a method and/or medicament for promoting fetal growth which will at least provide the public with a useful choice.
DISCLOSURE OF INVENTION
In a first aspect the invention relates to a method of reducing fetal growth retardation and/or promoting fetal growth in mammals comprising the step of increasing the active concentration(s) of IGF-1 and/or IGF-2 and/or analogues of said IGF-1 or IGF-2 within the maternal host during pregnancy.
The invention also consists in a medicament suitable for reducing fetal growth retardation and/or promoting fetal growth in meals comprising IGF-1, IGF-2 or analogues of said IGF-1 or IGF-2 or a mixture of two or more of these optionally provided in a pharmaceutically acceptable carrier or diluent.
The invention also relates to a medicament suitable for reducing fetal growth retardation and/or promoting fetal growth in mammals comprising a compound which, on administration to a pregnant female, increases the active concentration of IGF-1 and/or IGF-2 and/or naturally occuring analogues of said IGF-1 or IGF-2 optionally provided in a pharmaceutically acceptable carrier or diluent.
Further, the invention may be said to consist in the u
REFERENCES:
Biosis Abstract No. 87:84016; and J. Perinet. Med., vol. 14, No. 3, 1986; 163-169.
Pediatri Research, vol. 26, No. 6, 1988, pp. 663-667; J. W. Collins et al; "Human placental lactogen administration in the pregnant rat": acceleration of fetal growth.
Chemical Abstracts, vol. 101, No. 23, 1984; S. J. Pilistine et al: "Placental lactogen administration reverses the effect of low protein diet on maternal and fetal serum somatomedin levels in the pregnant rat" abst. No. 20435s.
Journal of Developmental Physiology, vol. 13, 1990, pp. 189-197; C. T. Jones et al; "Studies on the growth of the fetal guinea pig". The effects of nutritional manipulation on prenetal growth and plasma somatomedin activity and IGF factor concentrations.
Endocrimology, vol. 126, No. 4, 1990, pp. 2062-2067; M. L. Davenport et al.: "Effect of maternal fasting on fetal growth, serum insulin like growth factors, and tissue IGF messenger ribonucleic acid".
Chemical Abstracts, vol. 96, No. 17, 1982; D. J. Hill et al.: "Sometomedins and fetal growth", abst. No. 136725e.
C. T. Jones, H. N. Lafeber, T. P. Rolph, J. T. Parer, "Studies on the growth of the fetal guinea pig. The effects of nutritional manipulation on prenatal growth and plasma somatomedin activity and insulin-like growth factor concentrations", Jrnl of Development Physiology, 13, 189-197, 1990.
Effects of Insulin-Like Growth Factors I and II on Growth and "Differentiation of Transplanted Rat Embryos and Fetal Tissues", Endocrinology, vol. 124, No. 6, 3077-3082, 1989.
Ambler Geoffrey R.
Breier Bernhard H.
Gluckman Peter D.
Auckland UniServices Limited
Schain Howard E.
Touzeau P. Lynn
LandOfFree
IGF-1 and related compounds in pregnancy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IGF-1 and related compounds in pregnancy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IGF-1 and related compounds in pregnancy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-361846